It’s be­gin­ning to look a lot like M&A sea­son; Aduhelm runs in­to more re­sis­tance; Eli Lil­ly, Bris­tol My­ers get in ear­ly on can­cer ef­forts; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As JP Mor­gan moves #JPM22 ful­ly vir­tu­al, so will End­points News. We’re tak­ing our mul­ti-day hy­brid event sched­ule on­line, with no live cock­tail hour or net­work­ing events but plen­ty of time­ly news, in­sight­ful pan­els and fire­side chats pre­view­ing the new year. We’ll be sad to not see our friends and col­leagues on site, but we en­cour­age every­one to still reg­is­ter for the event and join the con­ver­sa­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER